AnaptysBio 配当金

配当金基準チェック /06

AnaptysBio配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.3%

バイバック利回り

総株主利回り	-0.3%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当金アップデート

更新なし

Recent updates

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

決済の安定と成長

配当データの取得

安定した配当: ANABの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ANABの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

AnaptysBio 配当利回り対市場

ANAB 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (ANAB)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.5%
業界平均 (Biotechs)	2.2%
アナリスト予想 (ANAB) (最長3年)	0%

注目すべき配当: ANABは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ANABは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: ANABの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ANABが配当金を報告していないため、配当金の持続可能性を計算できません。

AnaptysBio 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Chief Legal Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Consensus revenue estimates fall by 20%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to US$48.22

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 16%

Price target decreased by 10% to US$26.80

Price target decreased by 12% to US$28.20

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates decrease by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 43%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2025

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Consensus forecasts updated

Price target increased to US$31.50

Price target increased to US$31.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Consensus revenue estimates increase by 58%

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Consensus revenue estimates increase by 17%

Price target decreased to US$29.33

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Consensus revenue estimates fall by 10%

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

High number of new directors

COO & General Counsel notifies of intention to sell stock

Price target decreased to US$31.60

Consensus revenue estimates fall by 56%

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

配当金基準チェック /06